Targeted, Cell and Biomarker‑Driven Therapies Drive 8% CAGR to 2030

добавлена новая статья Health

2025-06-20 06:44:22

Global Market Overview The Diffuse Large B‑Cell Lymphoma (DLBCL) Therapeutics Market reached approximately USD 4.02 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 7.9%, reaching USD 6.36 billion by 2030. Additional forecasts suggest the market could exceed USD 5.4 billion by 2035, driven by rapid innovation, expanded treatment access, and increasing disease...

0 Комментарии 0 Поделились 41 Просмотры 0 предпросмотр